Drug intelligence / Profile preview

XYL-4001

Development stage: Preclinical
Lead developer: Xylo Bio
Modality: Small Molecules
Administration: Unspecified

Overview

XYL-4001, formerly known as PSYLO-4001, is an investigational non-hallucinogenic serotonin 5-HT2A receptor agonist and psychoplastogen. It is currently under development for the treatment of depressive disorders, including major depressive disorder. The drug is being developed by Xylo Bio (formerly Psylo) and was in the preclinical research stage as of January 2025. Its chemical structure has not yet been disclosed.

Targets

HTR2A (Serotonin receptor 5-HT2A)

Beyond the preview

Go deeper on XYL-4001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XYL-4001.

Explore the full profile